Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Conditions: Non-Alcoholic Fatty Liver Disease Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Oral Tablet Sponsors: Ann& Robert H Lurie Children ' s Hospital of Chicago Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alcoholism | Children | Empagliflozin | Fatty Liver Disease (FLD) | Hospitals | Jardiance | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pediatrics | Research | SGLT2 Inhibitors | Urology & Nephrology